BACKGROUND: Cirrhotic patients have been reported to have leukocyte impaired function as well as a high incidence of infectious diseases. Granulocyte-macrophage colony-stimulating factor (GM-CSF) increases the number and function of phagocytic cells, and clinical applications are under study. We tested in vitro effects of GM-CSF on phagocytosis, phagocytic index, and chemotaxis in polymorphonuclear leukocytes from 21 cirrhotic patients (12 with compensated cirrhosis and 9 with spontaneous bacterial peritonitis). METHODS: Polymorphonuclear leukocyte functions were tested under basal conditions and after incubation with GM-CSF (10 ng/mL). Phagocytosis was tested against a clinical strain of Candida albicans, and chemotaxis was evaluated using a Boyden chamber. Results were compared with those obtained from 14 healthy donors. RESULTS: Leukocytes from cirrhotics displayed lower basal functional activity than control cells in phagocytosis (P < 0.01) and chemotaxis (P < 0.01). After GM-CSF stimulation, the percentage of phagocytic polymorphonuclear leukocytes in noninfected patients increased from 60% +/- 2.5% to 69.9% +/- 2.42% (P < 0.01), phagocytic index from 0.79 +/- 0.07 to 1.02 +/- 0.07 (P < 0.001), and chemotaxis from 61.2 +/- 12.6 to 82.3 +/- 10.2 cells/high power field (P < 0.05). In patients with peritonitis, the phagocytic index increased from 0.87 +/- 0.08 to 1.08 +/- 0.05 (P < 0.01), phagocytosis from 57.8 +/- 3.57 to 64.7 +/- 2.34 and chemotaxis from 83.3 +/- 17.8 to 110.2 +/- 24.1. CONCLUSIONS: Our results indicate that a defective leukocyte function is present both in compensated and infected cirrhotic patients. An in vitro improvement was observed after GM-CSF stimulation.
BACKGROUND: Cirrhotic patients have been reported to have leukocyte impaired function as well as a high incidence of infectious diseases. Granulocyte-macrophage colony-stimulating factor (GM-CSF) increases the number and function of phagocytic cells, and clinical applications are under study. We tested in vitro effects of GM-CSF on phagocytosis, phagocytic index, and chemotaxis in polymorphonuclear leukocytes from 21 cirrhotic patients (12 with compensated cirrhosis and 9 with spontaneous bacterial peritonitis). METHODS: Polymorphonuclear leukocyte functions were tested under basal conditions and after incubation with GM-CSF (10 ng/mL). Phagocytosis was tested against a clinical strain of Candida albicans, and chemotaxis was evaluated using a Boyden chamber. Results were compared with those obtained from 14 healthy donors. RESULTS: Leukocytes from cirrhotics displayed lower basal functional activity than control cells in phagocytosis (P < 0.01) and chemotaxis (P < 0.01). After GM-CSF stimulation, the percentage of phagocytic polymorphonuclear leukocytes in noninfected patients increased from 60% +/- 2.5% to 69.9% +/- 2.42% (P < 0.01), phagocytic index from 0.79 +/- 0.07 to 1.02 +/- 0.07 (P < 0.001), and chemotaxis from 61.2 +/- 12.6 to 82.3 +/- 10.2 cells/high power field (P < 0.05). In patients with peritonitis, the phagocytic index increased from 0.87 +/- 0.08 to 1.08 +/- 0.05 (P < 0.01), phagocytosis from 57.8 +/- 3.57 to 64.7 +/- 2.34 and chemotaxis from 83.3 +/- 17.8 to 110.2 +/- 24.1. CONCLUSIONS: Our results indicate that a defective leukocyte function is present both in compensated and infected cirrhoticpatients. An in vitro improvement was observed after GM-CSF stimulation.
Authors: F F di Mola; H Friess; A Scheuren; P Di Sebastiano; H Graber; B Egger; A Zimmermann; M Korc; M W Büchler Journal: Ann Surg Date: 1999-01 Impact factor: 12.969
Authors: F Trevisani; E Castelli; F G Foschi; M Parazza; E Loggi; M Bertelli; C Melotti; M Domenicali; G Zoli; M Bernardi Journal: Gut Date: 2002-05 Impact factor: 23.059
Authors: David U Lee; Gregory H Fan; David J Hastie; Vibhav N Prakasam; Elyse A Addonizio; Ryan R Ahern; Kristen J Seog; Raffi Karagozian Journal: J Clin Exp Hepatol Date: 2021-02-04
Authors: Katharine M Irvine; Xuan Banh; Victoria L Gadd; Kyle K Wojcik; Juliana K Ariffin; Sara Jose; Samuel Lukowski; Gregory J Baillie; Matthew J Sweet; Elizabeth E Powell Journal: JCI Insight Date: 2016-06-02
Authors: J A Girón-González; C Rodríguez-Ramos; J Elvira; F Galán; C F Del Alamo; F Díaz; L Martín-Herrera Journal: Clin Exp Immunol Date: 2001-01 Impact factor: 4.330
Authors: Kevin J Fagan; Geraint B Rogers; Michelle Melino; Dionne M Arthur; Mary-Ellen Costello; Mark Morrison; Elizabeth E Powell; Katharine M Irvine Journal: PLoS One Date: 2015-03-17 Impact factor: 3.240